On July 23, Tempus AI rose 5.54% overnight, trading at $49.56/share, with turnover of $3.53 million. The rebound follows the stock's sharp sell-off earlier in the week after announcing its $1.5 billion acquisition of cancer detection company Personalis.

On July 20, Tempus AI dropped over 6% after revealing it would acquire Personalis at $16.25 per share in stock, aiming to integrate its molecular residual disease (MRD) detection technology into Tempus's AI-driven precision oncology platform. The cash component would be funded from existing reserves and credit facilities. Subsequently, Needham issued a supportive note stating the acquisition valuation of approximately 15.5 times estimated 2027 enterprise value-to-sales is warranted given Personalis's strong growth in its NeXT Personal platform, Medicare reimbursement wins, and large MRD market opportunity. The brokerage also noted competing bids and antitrust concerns are unlikely.

The overnight recovery suggests the market is increasingly digesting the strategic rationale behind the deal following analyst endorsement.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)